Released: June 25, 2025
Expiration: December 24, 2025
Acalabrutinib [prescribing information]. FDA. Wilmington, DE: AstraZeneca; 2025.
Acalabrutinib [product information]. EMA. Södertälje, Sweden: AstraZeneca AB; 2025.
American Society of Hematology COVID-19 Resources. Prevention of COVID-19 in immunocompromised patients with hematologic conditions. hematology.org/covid-19/archived-resources-for-clinicians/prevention-of-covid-19-in-immunocompromised-patients-with-hematologic-conditions. Accessed June 19, 2025.
Awan FT, Al-Sawaf O, Fischer K, Woyach JA. Current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1-10.
Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516-5525.
Bercusson A, Colley T, Shah A, et al. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985-1988.
Blez D, Blaize M, Soussain C, et al. Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica. 2020;1305:478-489.
Boddicker NJ, Larson MC, Castellino A, et al. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol. 2021;96:979-988.
Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796-1805.
Brown JR, Byrd JC, Chia Paolo, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335-1346.
Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-332.
Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-2437.
Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib vs ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.
Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332.
Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.
Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135:1204-1213.
Cameron, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74:263-271.
Castillo JJ, Branagan AR, Sermer D, et al. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia. Blood. 2024;143:582-591.
Chen ST, Azali L, Rosen L, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. Hematol Oncol. 2022;15:92.
Chiu CY, Ahmed S, Thomas SK, et al. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2023;23:610-615.
Coombs CC, Shah NN, Jurczak W, et al. Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 7513.
Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3:1799-1807.
de Jong J, Hellemans P, De Wilde S, et al. A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2018;59:2888-2895.
de Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100:548-557.
Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919-1928.
Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023;41:5099-5106.
Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57:512-519.
Geethakumari PR, Awan F. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13:1039-1046.
Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293-2306.
Ghasoub R, Albattah A, Elazzazy S, et al. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review. J Oncol Pharm Pract. 2020;26:487-491.
Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955-1959.
Ibrutinib [prescribing information]. FDA. South San Francisco, CA: Pharmacyclics; 2025.
Ibrutinib [product information]. EMA. Beerse, Belgium: Janssen-Cilag International NV; 2025.
Ikegawa N, Saito-Sasaki N, Sawada Y. Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature. Skin Health Dis. 2025;5:151-153.
Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581-2584.
Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991-3995.
Li C, Chen L, Li L, Chen W. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (Paxlovid) based on physiologically-based pharmacokinetic models. Eur J Pharm Sci. 2023;189:106564.
Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:336-345.
Marchesini G, Nadali G, Facchinelli D, et al. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. Br J Haematol. 2021;193:316-324.
Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016;127:1064-1067.
Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
Mato AR, Woyach JA, Brown JR, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up of from the phase I/2 BRUIN study. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 961.
McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829-3830.
Mikulska M, Oltolini C, Zappulo E, et al. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines. Blood Rev. 2024; 65:101180.
Nastoupil LJ, Hess G, Pavlovsky MA, et al. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023;7(22):7141–7150.
National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed June 19, 2025.
Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;174:103696.
O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409-1418.
O’Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704.
Paydas S. Management of adverse events/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56-63.
Pirtobrutinib [prescribing information]. FDA. Indianapolis, IN: Lilly USA; 2024.
Pirtobrutinib [product information]. EMA. Utrecht, The Netherlands: Eli Lilly Nederland BV; 2025.
Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30:346-50.
Seymour JF, Byrd JC, Ghia Paolo, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. Blood. 2023;142:687-699.
Sibaud V, Beylot-Barry M, Protin C, et al. Dermatological toxicities of Bruton's tyrosine kinase inhibitors. Am J Clin Dermatol. 2020;21:799-812.
Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025;110:92-102.
Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112-120.
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab vs chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023;88:1271-1281.
Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862.
Takahashi N, Tsukasaki K, Tanae K, et al. Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma. J Clin Exp Hematop. 2021;62:18-24.
Tam CS, Opat S, Zhu J, et al. Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies. Presented at: 2019 European Hematology Association annual meeting; June 13-16, 2019a. Abstract PS1159.
Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019b;134:851-859.
Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038-2050.
Tam CSL, Garcia-Sanz, Opat S, et al. ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM). J Clin Oncol. 2022a;40:7521.
Tam CSL, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022b;6:1296-1308.
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136:2027-2037.
Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89:1055-1062.
Wang M, David Salek D, Belada D, et al. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025;[Epub ahead of print].
Wang ML, Shah NN, Jurczak, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase I/II BRUIN study. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022a. Abstract 4218.
Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022b;386:2482-2494.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-516.
Wang ML, Blum KA, Martin P. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739-745.
Wang M, Rule S, Zinzani PL, et al. Long‑term follow‑up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. Presented at: 2018 American Society of Hematology annual meeting; December 1-4, 2018. Abstract 2876.
Wang M, Rule S, Zinzani PL, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Presented at: 2020 American Society of Hematology annual meeting; December 5-8, 2020. Abstract 2040.
Witkowska M, Drozd-Sokołowska J, Waszczuk-Gajda A, et al. Autoimmune cytopenias in patients with malignant lymphoma: A multicenter report by the Polish Lymphoma Research Group. Adv Clin Exp Med. 2024;33:1097.
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens vs chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285-1295.
Zanubrutinib [prescribing information]. FDA. San Mateo, CA: BeiGene USA; 2025.
Zanubrutinib [product information]. EMA. Dublin, Ireland: BeiGene Ireland Ltd; 2025.
Access to and use of this Interactive Decision Support Tool titled, “Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices in monitoring and managing adverse events that can occur in patients with mantle cell lymphoma treated with BTK inhibitor therapy with expert guidance from Georg Hess, MD, and Carlo Visco, MD.
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States FDA and/or the European Medicines Agency (EMA). A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
© 2025 Clinical Care Options, LLC. All rights reserved.